X4 PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
X4 PHARMACEUTICALS, INC (XFOR) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 431.92 thousand shares for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2022-11-03
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2022-09-30 was 276.00K shares, a 348.51% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2022-06-30 was 121.11K shares, a 491.08% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2022-03-31 was 34.81K shares, a 24.99% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2021-09-30 was 61.54K shares, a 97.64% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month |
|---|---|---|---|
| 2022-09-30 | 276.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 397.11K shares derived: sum of 2 quarters · filed 2022-11-03 | 431.92K shares 10-Q · filed 2022-11-03 |
| 2022-06-30 | 121.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 155.93K shares 10-Q · filed 2022-08-04 | |
| 2022-03-31 | 34.81K shares 10-Q · filed 2022-05-12 | ||
| 2021-09-30 | 61.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 82.03K shares derived: sum of 2 quarters · filed 2021-11-04 | 109.88K shares 10-Q · filed 2021-11-04 |
| 2021-06-30 | 20.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | 48.34K shares 10-Q · filed 2021-08-03 | |
| 2021-03-31 | 27.85K shares 10-Q · filed 2021-05-06 | ||
| 2020-09-30 | 31.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 39.29K shares 10-Q · filed 2020-11-05 | |
| 2020-06-30 | 8.15K shares 10-Q · filed 2020-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |